Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 392

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia

Preudhomme, Claude, Guilhot, Joëlle, Nicolini, Franck Emmanuel, Guerci-Bresler, Agnès, Rigal-Huguet, Françoise, Maloisel, Frederic, Coiteux, Valérie, Gardembas, Martine, Berthou, Christian, Vekhoff, Anne, Rea, Delphine, Jourdan, Eric, Allard, Christian, Delmer, Alain, Rousselot, Philippe, Legros, Laurence, Berger, Marc, Corm, Selim, Etienne, Gabriel, Roche-Lestienne, Catherine, Eclache, Virginie, Mahon, François-Xavier, Guilhot, François·2010·New England Journal of Medicine

Abstract

BACKGROUND: Imatinib (400 mg daily) is considered the best initial therapy for patients with newly diagnosed chronic myeloid leukemia (CML) in the chronic phase. However, only a minority of patients treated with imatinib have a complete molecular remission. METHODS: We randomly assigned 636 patients with untreated chronic-phase CML to receive imatinib alone at a dose of 400 mg daily, imatinib (400 mg daily) plus cytarabine (20 mg per square meter of body-surface area per day on days 15 through 28 of each 28-day cycle) or pegylated interferon (peginterferon) alfa-2a (90 μg weekly), or imatinib alone at a dose of 600 mg daily. Molecular and cytogenetic responses, time to treatment failure, overall and event-free survival, and adverse events were assessed. An analysis of molecular response at 12 months was planned. A superior molecular response was defined as a decrease in the ratio of transcripts of the tyrosine kinase gene BCR-ABL to transcripts of ABL of 0.01% or less, corresponding to a reduction of 4 log(10) units or more from the baseline level, as assessed by means of a real-time quantitative polymerase-chain-reaction assay. RESULTS: At 12 months, the rates of cytogenetic response were similar among the four groups. The rate of a superior molecular response was significantly higher among patients receiving imatinib and peginterferon alfa-2a (30%) than among patients receiving 400 mg of imatinib alone (14%) (P=0.001). The rate was significantly higher among patients treated for more than 12 months than among those treated for 12 months or less. Gastrointestinal events were more frequent among patients receiving cytarabine, whereas rash and depression were more frequent among patients receiving peginterferon alfa-2a. CONCLUSIONS: As compared with other treatments, the addition of peginterferon alfa-2a to imatinib therapy resulted in significantly higher rates of molecular response in patients with chronic-phase CML. (Funded by the French Ministry of Health and others; ClinicalTrials.gov number, NCT00219739.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1004095

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 392

Metadata

Authors
Preudhomme, C., Guilhot, J., Nicolini, F. E., Guerci-Bresler, A., Rigal-Huguet, F., Maloisel, F., Coiteux, V., Gardembas, M., Berthou, C., Vekhoff, A., Rea, D., Jourdan, E., Allard, C., Delmer, A., Rousselot, P., Legros, L., Berger, M., Corm, S., Etienne, G., Roche-Lestienne, C., Eclache, V., Mahon, F.-X., & Guilhot, F.
Venue
New England Journal of Medicine
Published
2010-12-23
Volume
363
Issue
26
Pages
2511-2521
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2322365534
Cited by
392
References
3
FWCI
25.14
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia. https://app.cochat.ai/papers/10.1056/nejmoa1004095
The paper
Preudhomme, C., Guilhot, J., Nicolini, F. E., Guerci-Bresler, A., Rigal-Huguet, F., Maloisel, F., Coiteux, V., Gardembas, M., Berthou, C., Vekhoff, A., Rea, D., Jourdan, E., Allard, C., Delmer, A., Rousselot, P., Legros, L., Berger, M., Corm, S., Etienne, G., . . . Guilhot, F. (2010). Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1004095

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.